MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Apolipo蛋白 E/APOE3 蛋白

MCE 國(guó)際站：Apolipoprotein E/APOE3 Protein, Human (HEK293, His)

品牌：MedChemExpress (MCE)

貨號(hào)：HY-P7531

純度：Greater than 95% as determined by reducing SDS-PAGE.

存儲(chǔ)條件：在 -20°C 下可保存 2 年,。復(fù)溶后,，在 4°C 下可穩(wěn)定保存 1 周，在 -20°C 下可穩(wěn)定保存更長(zhǎng)時(shí)間（含載體蛋白）,。建議將等分試樣在 -20°C 或 -80°C 下冷凍以延長(zhǎng)保存時(shí)間,。

運(yùn)輸條件：美國(guó)大陸的室溫；其他地方可能有所不同,。

產(chǎn)品活性：Apolipoprotein E/ApoE3 是一種介導(dǎo)脂質(zhì)運(yùn)輸?shù)妮d脂蛋白亞型,，通過結(jié)合 LDL receptor (LDLR), LDL receptor-related proteins (LRP1, LRP2, LRP8) 和 Very Low-Density Lipoprotein Receptor (VLDLR) 以及肝素 (Heparin)，在血漿和中樞神經(jīng)中脂質(zhì)穩(wěn)態(tài)中發(fā)揮關(guān)鍵作用,。Apolipoprotein E/ApoE3 蛋白, Human (HEK293, His) 是一種重組蛋白,，N 端帶有一個(gè) His 標(biāo)簽，由 299 個(gè) (K19-H317) 氨基酸組成,，在 HEK293 細(xì)胞中表達(dá),。

生物活性：使用SH-SY5Y細(xì)胞進(jìn)行細(xì)胞增殖測(cè)定，該作用的ED50為≤17.23ng/mL,，對(duì)應(yīng)比活性為≥5.8×104單位/mg,。

體外：Apolipoprotein E/ApoE3 (3 μM，24 小時(shí)) 在新生大鼠星形膠質(zhì)細(xì)胞 (NRA) 中對(duì) β-Amyloid (1-42) (HY-P1388) 誘導(dǎo)的炎癥反應(yīng)具有一定的保護(hù)作用[5],。 Apolipoprotein E/ApoE3 (10 μg/mL,，48 小時(shí)) 可增強(qiáng)小鼠胚胎成纖維細(xì)胞 (MEF) 神經(jīng)元中 Aβ 合成[7]。

體內(nèi)：Apolipoprotein E/ApoE3 (Human) 可在轉(zhuǎn)基因 C57BL/6J 小鼠中 (用 hAPOE3 等位基因靶向替代小鼠 Apolipoprotein E 基因) 增強(qiáng)飲食誘導(dǎo)的高膽固醇血癥和動(dòng)脈粥樣硬化[6],。 Apolipoprotein E/ApoE3 (Human) 在 hApoE3 轉(zhuǎn)基因小鼠的星形膠質(zhì)細(xì)胞中通過產(chǎn)生高密度脂蛋白 (HDL) 樣顆粒將膽固醇釋放到胞外[8],。

研究背景：Apolipoprotein E/APOE3 是兩親性分子，既能與脂蛋白顆粒核心的脂質(zhì)相互作用,，也能與血漿的水環(huán)境相互作用[3],。 Apolipoprotein E/APOE3 通過與 LDL receptor (LDLR), LDL receptor-related proteins (LRP1, LRP2, LRP8) 和 Very Low-Density Lipoprotein Receptor (VLDLR) 以及肝素 (Heparin) 結(jié)合，調(diào)控血漿和神經(jīng)中樞脂質(zhì)代謝[9][10][12],。 Apolipoprotein E/APOE3 首先通過與 ABCA1 互作,，促進(jìn) HDL (高密度脂蛋白) 合成，其次將 HDL 從外周組織運(yùn)送到肝臟,，從而清除其中的膽固醇，Apolipoprotein E/APOE3 對(duì)調(diào)節(jié)膽固醇穩(wěn)態(tài)具有重要作用[11],。 Apolipoprotein E/APOE 可以與免疫細(xì)胞受體 LILRB4 結(jié)合調(diào)控免疫反應(yīng)[13],。 Apolipoprotein E/APOE3 可激活 MAP3K12 和非典型 MAPK 信號(hào)轉(zhuǎn)導(dǎo)通路，增強(qiáng) AP-1 介導(dǎo)的 APP 轉(zhuǎn)錄[14],。

種屬：Human

標(biāo)簽：C-6*His

蛋白編號(hào)：P02649 (K19-H317)

基因 ID：348

同用名：rHuApolipoprotein E, His; ApoE; Apolipoprotein E; APOE3

熱銷產(chǎn)品：Dantrolene  | Meprednisone  | Gastrin I, rat  | L-798106  | Preladenant  | Oleuropein  | Bis-PEG13-NHS ester  | Navitoclax-piperazine  | WRVYEKC(dnp)ALK (tetraTFA)  | Fidarestat

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻(xiàn)：

[1]. Gong JS, et al. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from humanApoE3 and ApoE4 knock-in mice. J Biol Chem. 2002 Aug 16;277(33):29919-26.
[2]. Gong JS, et al. Novel action of apolipoprotein E (ApoE): ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons. Mol Neurodegener. 2007 May 15;2:9.
[3]. Hatters DM, et al. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006 Aug;31(8):445-54.
[4]. Wetterau JR, et al. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem.
[5]. Dorey E, et al. Apolipoprotein E Isoforms Differentially Regulate Alzheimer's Disease and Amyloid-β-Induced Inflammatory Response in vivo and in vitro. J Alzheimers Dis. 2017;57(4):1265-1279.
[6]. Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem.
[7]. Huang Y W A, et al. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion[J]. Cell, 2017, 168(3): 427-441. e21.
[8]. Gong J S, et al. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice[J]. Journal of Biological Chemistry, 2002, 277(33): 29919-29926.
[9]. Sehayek E, et al. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
[10]. Kowal RC, et al. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5810-4.
[11]. Ji ZS, et al. Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem.
[12]. Fagan AM, et al. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem. 1996 Nov 22;271(47):30121-5.
[13]. Deng M, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018 Oct;562(7728):605-609.
[14]. Huang YA, et al. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion. Cell. 2017 Jan 26;168(3):427-441.e21.